Appendix Table 1a. Lifetime comorbidities of Generalized Anxiety Disorder with other anxiety, mood, and substance use disorders, in the ECA-SP (Brazil)

Appendix Table 1b. Lifetime comorbidities of Generalized Anxiety Disorder with other anxiety, mood, and substance use disorders, in the MHS-OHS (Canada)

Appendix Table 1c. Lifetime comorbidities of Generalized Anxiety Disorder with other anxiety, mood, and substance use disorders, in the NEMESIS (Netherlands)

Appendix Table 1d. Lifetime comorbidities of Generalized Anxiety Disorder with other anxiety, mood, and substance use disorders, in the NCS (United States)

Appendix Table 2. Effects of significant prior anxiety and mood disorders in predicting first onset of Generalized Anxiety Disorder (GAD), by country

Appendix Table 3. Effects of significant prior anxiety and mood disorders in predicting first onset of GAD by sex and cohort in the combined four-country sample

Appendix Table 4. Effects of significant anxiety and mood disorders in predicting pure versus comorbid GAD in the combined four-country sample

Appendix Table 5. Effects of anxiety, mood, and substance use disorders in predicting persistence of GAD in the combined four-country sample